1. In Vivo
  2. >>Archive

Glaxo Puts SNPs to Work

Glaxo Wellcome was naturally disappointed that it had to withdraw troglitazone (Romozin), a new treatment for Type II diabetes, from the UK market in December 1997, just four months after launch. The problems with troglitazone only really started showing up once the drug came to market, and started being used in patient populations far larger than those assembled for clinical trials. "If we could've identified people who would have adverse events, then we would've had a market for that drug," asserts Alan Roses, MD, a clinical neurologist who became Glaxo's VP and worldwide director, genetics, in June 1997. In fact.Glaxo could have predicted the complications with troglitazone by examining patients' genetic profiles, Roses asserts.

When life gives you lemons, make lemonade. Glaxo Wellcome PLC seems to be taking this homily to heart. The firm was naturally disappointed that it had to withdraw troglitazone (Romozin), a new treatment for Type II diabetes, from the UK market in December 1997, just four months after launch. Although the action was voluntary, Glaxo felt it had little choice. By then, the drug's originator Sankyo Co. Ltd. , and its North American licensee Parke-Davis , a division of Warner-Lambert Co. , (which sold it as Rezulin), had catalogued too many adverse effects on patients' livers to allow it to get through European approvals.

The problems with troglitazone only really started showing up once the drug came to market, and started being used in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.